Genitourinary Cancers Symposium (ASCO GU) | Conference

Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC

February 18th 2022

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer

February 18th 2022

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC

February 17th 2022

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Deep PSA Response Is Associated with Positive Wellbeing Scores in Advanced Prostate Cancer

February 17th 2022

Treatment with apalutamide, an androgen receptor inhibitor, was associated with a deep PSA response leading to beneficial outcomes in patient-related end points.

Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis

February 17th 2022

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Dr. Saad on the Efficacy of First-Line Olaparib Plus Abiraterone in mCRPC

February 17th 2022

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Dr. Merseburger on the Efficacy of Continuing Enzalutamide in mCRPC

February 17th 2022

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.

Dr. Armstrong on Findings From a Post-Hoc Analysis of the ARCHES Trial in mHSPC

February 17th 2022

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

February 15th 2021

Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC

February 14th 2021

February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib in Advanced RCC

February 13th 2021

February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.

Belzutifan/Cabozantinib Shows Promising Early Antitumor Activity in Advanced Clear Cell RCC

February 13th 2021

February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.

Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC

February 13th 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

BCG Plus N-803 Elicits Positive Responses, Tolerability in BCG-Unresponsive NMIBC CIS

February 13th 2021

February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ

Reduction in PSA Screening Associated with Increased Incidence of Metastatic Prostate Cancer in the United States

February 13th 2021

February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

ASCO GU 2021 News: Drs. Bradley McGregor, David Braun, and

February 13th 2021

Dr. Piliè on Impact of Adiposity on Response to Androgen Signaling Inhibition in mCRPC

February 13th 2021

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.

Dr. Dorff on the Benefit of Bright White Light Therapy on Obese Frailty in Prostate Cancer

February 13th 2021

Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.